CELU

Celularity Inc.

1.60 USD

Last updated Oct 7, 19:44 UTC

Yesterday HIGH

$1.77

Yesterday LOW

$1.54

52w HIGH

$2.55

52w LOW

$0.56

EPS

0.02

PE

80.00

Next Earnings

Oct 20, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Celularity Inc. stock is up 3.9% since 30 days ago. The next earnings date is Oct 20, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 14.29% of the previous 7 October’s closed higher than September. In the last 1 Unusual Options Trades, there were 1 CALL.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

05 Oct 14:42	21 May, 2027	2.00	CALL	1000	0

Advanced Data Unlock

Benzinga Insights

Mon Jul 6, 2026

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The company's
Benzinga Insights

Mon Jul 6, 2026

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's regular session. The market value of their outstanding shares is at $4.8 million. Seer (NASDAQ:SEER) shares rose
Benzinga Newsdesk

Tue Jun 30, 2026

Celularity Secures $1M Secured Loan From Philip & Daniele Barach Family Trust On June 29, 2026

On June 29, 2026, Celularity Inc. (the "Company") entered into a Loan Agreement (the "Loan Agreement") with the Philip & Daniele Barach Family Trust (the "Lender"), a trust affiliated with
Benzinga Newsdesk

Fri May 29, 2026

Celularity Receives Nasdaq Noncompliance Notice

- Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications
Benzinga Newsdesk

Thu May 28, 2026

Celularity Enters Settlement With Helena Global To Restructure Convertible Note Obligations, Including $500K Upfront And $100K Monthly Payments Plus Note Assignment

Entry into a Material Definitive Agreement. As previously disclosed by Celularity Inc. (the "Company") in its Current Report on Form 8-K filed on April 21, 2026, Helena Global Investment Opportunities 1 Ltd.
Benzinga Insights

Fri May 1, 2026

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Newsdesk

Fri May 1, 2026

Celularity Regains Nasdaq Listing Compliance After Filing Late Form 10-K With SEC On April 30
Benzinga Insights

Tue Apr 21, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Newsdesk

Tue Apr 21, 2026

NexGel And Celularity Enter Amendment No. 1 To License Agreement On April 17, 2026; Co To Pay Celularity $13.3M Including $8.3M Cash And $5M Convertible Note

-SEC Filing
Benzinga Newsdesk

Fri Apr 17, 2026

Celularity Receives Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications

Philip Daniele Barach Family Trust, 10% Owner

Wed Sep 23, 2026

CELU Recent Insider Trades and Stock Chart

6,425,301 shares other
Daniele W. Barach, 10% Owner

Wed Sep 23, 2026

CELU Recent Insider Trades and Stock Chart

6,425,301 shares other
Philip Alan Barach, Director

Wed Sep 23, 2026

CELU Recent Insider Trades and Stock Chart

6,425,301 shares other